Jaargang 28 (2008)
Nummer: 01
Artikel: 63

Pictogram

DT-28-01-63.pdf 482.03 KB 89 downloads

Misverstanden en mythes ...

Referenties

Barbui, C., Nose, M., Mazzi, M.A., Thornicroft, G., Schene, A., Becker, T., Bindman, J., Leese, M., Helm, H., Koeter, M., Weinmann, S., & Tansella, M. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21, 355-362.

Freudenreich, O., & Goff, D.C. (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica,
106, 323-330.

Ito, H., Koyama, A., & Higuchi, T. (2005). Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. British Journal of Psychiatry,
187, 243-247.

Suzuki, T., Uchida, H., Tanaka, K.F., Nomura, K., Takano, H., Tanabe, A., Watanabe, K., Yagi, G., & Kashima, H. (2004). Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. International Journal of Neuropsychopharmacology, 7, 133-142.

Waddington, J.L., Youssef, H.A., & Kinsella, A. (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 173, 325-329.

Pictogram

DT-28-01-63.pdf 482.03 KB 89 downloads

Misverstanden en mythes ...